PMOS: Kaletra Double Protease Inhibitors.

Trial Profile

PMOS: Kaletra Double Protease Inhibitors.

Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2013

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Peptide hydrolase inhibitors
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms PMOS
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 22 Mar 2012 Actual patient number changed from 70 to 65 as reported by
    • 13 Dec 2011 Status changed from recruiting to completed as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top